Abstract
Severe acute respiratory syndrome is a viral respiratory infection known as COVID-19, which is caused by a novel coronavirus, called SARS-associated coronavirus-2 (SARS-CoV-2). Considering it as an international concern, WHO declared COVID-19 as the “sixth public health emergency” and has termed it as ‘pandemic”. Currently, no specific drugs are available, and studies about COVID-19 treatment are still in progress. As the world is facing a major challenge in trying to adapt and defend itself against this new pandemic disease, computational intelligence offers a new hope that a cure to this disease might be developed faster than ever before. Many targets for the design of drugs have been already identified, and studies are in progress to explore these potential targets. Computational approaches like virtual screening, molecular docking, machine learning, deep learning and natural language processing (NLP) play a vital role in drug repurposing studies. Repurposing drugs involves discovering novel drug-target interactions and their use against the treatment of different diseases. This strategy has regained significant interest to develop a drug against the COVID-19 considering this pandemic scenario, and offers the best chance to identify potent drugs from the list of approved drugs. Various research efforts are currently focusing on the identification of existing drugs which might be useful in mitigating the infection and some compounds namely favipiravir, remdesivir, lopinavir, hydroxychloroquine etc. are in the final stage of human testing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Li, H., Liu, S.-M., Yu, X.-H., et al. (2020). Coronavirus disease 2019 (COVID-19): Current status and future perspectives. International Journal of Antimicrobial Agents 105951. https://doi.org/10.1016/j.ijantimicag.2020.105951.
Peng, X., Xu, X., Li, Y., et al. (2020). Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science, 12(9). https://doi.org/10.1038/s41368-020-0075-9.
Harcourt, J., Tamin, A., Lu, X., et al. (2020). Severe acute respiratory syndrome coronavirus 2 from patient with 2019 novel coronavirus disease, United States. Emerging Infectious Diseases Journal, 26. https://doi.org/10.3201/eid2606.200516
Su, L., Ma, X., Yu, H., et al. (2020). The different clinical characteristics of corona virus disease cases between children and their families in China—The character of children with COVID-19. Emerging Microbes Infectious, 9, 707–713. https://doi.org/10.1080/22221751.2020.1744483
Gorbalenya, A. E., Baker, S. C., Baric, R. S., et al. (2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology, 5, 536–544. https://doi.org/10.1038/s41564-020-0695-z
Lai, C.-C., Shih, T.-P., Ko, W.-C., et al. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents 55,105924. https://doi.org/10.1016/j.ijantimicag.2020.105924.
Shereen, M. A., Khan, S., Kazmi, A., et al. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, 24, 91–98. https://doi.org/10.1016/j.jare.2020.03.005.
Wu, R., Wang, L., Kuo, H.-C.D., et al. (2020). An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports, 6, 56–70. https://doi.org/10.1007/s40495-020-00216-7
Vaishya, R., Javaid, M., Khan, I. H., & Haleem, A. (2020). Artificial Intelligence (AI) applications for COVID-19 pandemic. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14, 337–339. https://doi.org/10.1016/j.dsx.2020.04.012.
Alimadadi, A., Aryal, S., Manandhar, I., et al. (2020). Artificial intelligence and machine learning to fight COVID-19. Physiological Genomics, 52, 200–202. https://doi.org/10.1152/physiolgenomics.00029.2020
Khan, R. J., Jha, R. K., Amera, G. M., et al. (2020). Targeting SARS-CoV-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2’-O-ribose methyltransferase. Journal of Biomolecular Structure and Dynamics, 1–14. https://doi.org/10.1080/07391102.2020.1753577.
Cherian, S., Agrawal, M., Basu, A., et al. (2020). Perspectives for repurposing drugs for the coronavirus disease 2019. Indian Journal of Medical Research, 151, 160–171. https://doi.org/10.4103/ijmr.IJMR_585_20
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. Nature Chemical Biology, 9, 232–240. https://doi.org/10.1038/nchembio.1199
Hodos, R. A., Kidd, B. A., Shameer, K., et al. (2016). In silico methods for drug repurposing and pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 8, 186–210. https://doi.org/10.1002/wsbm.1337
Jin, G., & Wong, S. T. C. (2014). Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today, 19, 637–644. https://doi.org/10.1016/j.drudis.2013.11.005
Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7, 146–157. https://doi.org/10.2174/157340911795677602
Pinzi, L., & Rastelli, G. (2019). Molecular docking: Shifting paradigms in drug discovery. International Journal of Molecular Sciences, 20, 4331. https://doi.org/10.3390/ijms20184331
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W., Jr. (2013). Computational methods in drug discovery. Pharmacological Reviews, 66, 334–395. https://doi.org/10.1124/pr.112.007336
Lionta, E., Spyrou, G., Vassilatis, D. K., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Current Topics in Medicinal Chemistry, 14, 1923–1938. https://doi.org/10.2174/1568026614666140929124445
Tripathi, M. K., Sharma, P., Tripathi, A., et al. (2020). Computational exploration and experimental validation to identify a dual inhibitor of cholinesterase and amyloid-beta for the treatment of Alzheimer’s disease. Journal of Computer-Aided Molecular Design. https://doi.org/10.1007/s10822-020-00318-w
Swamidass, S. J. (2011). Mining small-molecule screens to repurpose drugs. Briefings in Bioinformatics, 12, 327–335. https://doi.org/10.1093/bib/bbr028
Li, J., & Lu, Z. (2013). Pathway-based drug repositioning using causal inference. BMC Bioinformatics, 14, S3. https://doi.org/10.1186/1471-2105-14-S16-S3
Yella, J. K., Yaddanapudi, S., Wang, Y., & Jegga, A. G. (2018). Changing trends in computational drug repositioning. Pharmaceuticals (Basel), 11.
Napolitano, F., Zhao, Y., Moreira, V. M., et al. (2013). Drug repositioning: A machine-learning approach through data integration. Journal of Cheminformatics, 5, 30. https://doi.org/10.1186/1758-2946-5-30
Lo, Y.-C., Rensi, S. E., Torng, W., & Altman, R. B. (2018). Machine learning in chemoinformatics and drug discovery. Drug Discovery Today, 23, 1538–1546. https://doi.org/10.1016/j.drudis.2018.05.010.
Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18, 463–477. https://doi.org/10.1038/s41573-019-0024-5
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016). Deep learning for computational biology. Molecular Systems Biology, 12, 878. https://doi.org/10.15252/msb.20156651.
Dobchev, D., & Karelson, M. (2016). Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework? Expert Opinion on Drug Discovery, 11, 627–639. https://doi.org/10.1080/17460441.2016.1186876
Tayarani, A., Baratian, A., Naghibi Sistani, M.-B., et al. (2013). Artificial neural networks analysis used to evaluate the molecular interactions between selected drugs and human cyclooxygenase2 receptor. Iranian Journal of Basic Medicine and Science, 16, 1196–1202.
Chauhan, H., Bernick, J., Prasad, D., & Masand, V., et al. (2016). Chapter—The role of artificial neural networks on target validation in drug discovery and development. In Y. Pathak & V. K. Sutariya (Eds.), Puri M (pp. 15–27). Boston: Academic Press.
Najafabadi, M. M., Villanustre, F., Khoshgoftaar, T. M., et al. (2015). Deep learning applications and challenges in big data analytics. Journal of Big Data, 2, 1. https://doi.org/10.1186/s40537-014-0007-7
Ekins, S. (2016). The next era: Deep learning in pharmaceutical research. Pharmaceutical Research, 33, 2594–2603. https://doi.org/10.1007/s11095-016-2029-7
Schneider, P., Walters, W. P., Plowright, A. T., et al. (2020). Rethinking drug design in the artificial intelligence era. Nature Reviews Drug Discovery, 19, 353–364. https://doi.org/10.1038/s41573-019-0050-3
Hu, S., Zhang, C., Chen, P., et al. (2019). Predicting drug-target interactions from drug structure and protein sequence using novel convolutional neural networks. BMC Bioinformatics, 20, 689. https://doi.org/10.1186/s12859-019-3263-x
Ozturk, T., Talo, M., Yildirim, E. A., et al. (2020). Automated detection of COVID-19 cases using deep neural networks with X-ray images. Computers in Biology and Medicine, 121, 103792. https://doi.org/10.1016/j.compbiomed.2020.103792
Blaschke, T., Olivecrona, M., Engkvist, O., et al. (2018). Application of generative autoencoder in de novo molecular design. Molecular Informatics, 37, 1700123. https://doi.org/10.1002/minf.201700123
LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521, 436–444. https://doi.org/10.1038/nature14539
Hu, Q., Feng, M., Lai, L., & Pei, J. (2018). Prediction of drug-likeness using deep autoencoder neural networks. Frontiers in Genetics, 9, 585.
Zhou, Y., Hou, Y., Shen, J., et al. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6, 14. https://doi.org/10.1038/s41421-020-0153-3
Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019). Network-based prediction of drug combinations. Nature Communication, 10, 1197. https://doi.org/10.1038/s41467-019-09186-x
Dash, S., Shakyawar, S. K., Sharma, M., & Kaushik, S. (2019). Big data in healthcare: Management, analysis and future prospects. Journal of Big Data, 6, 54. https://doi.org/10.1186/s40537-019-0217-0
Harpaz, R., Callahan, A., Tamang, S., et al. (2014). Text mining for adverse drug events: The promise, challenges, and state of the art. Drug Safety, 37, 777–790. https://doi.org/10.1007/s40264-014-0218-z
Shah, N. H., Cole, T., Musen, M. A. (2012). Chapter 9: Analyses using disease ontologies. PLoS Computer Biology, 8, e1002827–e1002827. https://doi.org/10.1371/journal.pcbi.1002827.
Pal, M., Berhanu, G., Desalegn, C., & Kandi, V. (2020). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): An update. Cureus, 12, e7423–e7423. https://doi.org/10.7759/cureus.7423
Belouzard, S., Millet, J. K., Licitra, B. N., & Whittaker, G. R. (2012). Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 4, 1011–1033. https://doi.org/10.3390/v4061011
Shang, J., Wan, Y., Luo, C., et al. (2020). Cell entry mechanisms of SARS-CoV-2. Proceedings of National Academic Science, 117, 11727 LP–11734. https://doi.org/10.1073/pnas.2003138117.
Zhang, H., Penninger, J. M., Li, Y., et al. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46, 586–590. https://doi.org/10.1007/s00134-020-05985-9
Liang, Y., Wang, M.-L., Chien, C.-S., et al. (2020). Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Frontiers in Immunology, 11, 1022.
Liu, X., & Wang, X.-J. (2020). Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv 2020.01.29.924100. https://doi.org/10.1101/2020.01.29.924100.
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA, 323, 1824–1836. https://doi.org/10.1001/jama.2020.6019
Chang, C., Hou, M.-H., Chang, C.-F., et al. (2014). The SARS coronavirus nucleocapsid protein–forms and functions. Antiviral Research, 103, 39–50. https://doi.org/10.1016/j.antiviral.2013.12.009
Surjit, M., & Lal, S. K. (2008). The SARS-CoV nucleocapsid protein: A protein with multifarious activities. Infection, Genetics and Evolution, 8, 397–405. https://doi.org/10.1016/j.meegid.2007.07.004
Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: Current knowledge. Virology Journal, 16, 69. https://doi.org/10.1186/s12985-019-1182-0
Barretto, N., Jukneliene, D., Ratia, K., et al. (2005). The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. Journal of Virology, 79, 15189–15198. https://doi.org/10.1128/JVI.79.24.15189-15198.2005
Prajapat, M., Sarma, P., Shekhar, N., et al. (2020). Drug targets for corona virus: A systematic review. Indian Journal of Pharmacology, 52, 56–65. https://doi.org/10.4103/ijp.IJP_115_20
Xue, X., Yu, H., Yang, H., et al. (2008). Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design. Journal of Virology, 82, 2515 LP–2527. https://doi.org/10.1128/JVI.02114-07.
Goyal, B., & Goyal, D. (2020). Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy. ACS Combinatorial Science, 22, 297–305. https://doi.org/10.1021/acscombsci.0c00058
Tripathi, M. K., Singh, P., Sharma, S., et al. (2020). Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor. Journal of Biomolecular Structural Dynamics, 1–14. https://doi.org/10.1080/07391102.2020.1790425.
Jin, Z., Du, X., Xu, Y., et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582, 289–293. https://doi.org/10.1038/s41586-020-2223-y
Rut, W., Zmudzinski, M., Lyu, Z., et al. (2020). Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design. bioRxiv 2020.04.29.068890. https://doi.org/10.1101/2020.04.29.068890.
Gao, Y., Yan, L., Huang, Y., et al. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science, 368, 779–782. https://doi.org/10.1126/science.abb7498
Wu, C., Liu, Y., Yang, Y., et al. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 10, 766–788. https://doi.org/10.1016/j.apsb.2020.02.008
Adedeji, A. O., Marchand, B., Te Velthuis, A. J. W., et al. (2012). Mechanism of nucleic acid unwinding by SARS-CoV helicase. PLoS ONE, 7, e36521–e36521. https://doi.org/10.1371/journal.pone.0036521
Astuti, I., & Ysrafil, . (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes and Metabolics Syndrome Journal, 14, 407–412. https://doi.org/10.1016/j.dsx.2020.04.020
Fehr, A. R., & Perlman, S. (2015). Coronaviruses: An overview of their replication and pathogenesis. Methods in Molecular Biology, 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
Pham, Q.-V., Nguyen, D., Huynh-The, T., et al. (2020). Artificial intelligence (AI) and big data for coronavirus (COVID-19) pandemic: A survey on the state-of-the-arts.
Ho, D. (2020). Addressing COVID-19 drug development with artificial intelligence. Advanced Intelligent Systems, 2, 2000070. https://doi.org/10.1002/aisy.202000070
Tsikala Vafea, M., Atalla, E., Georgakas, J., et al. (2020). Emerging technologies for use in the study, diagnosis, and treatment of patients with COVID-19. Cellular and Molecular Bioengineering, 1–9. https://doi.org/10.1007/s12195-020-00629-w.
Beck, B. R., Shin, B., Choi, Y., et al. (2020). Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv 2020.01.31.929547. https://doi.org/10.1101/2020.01.31.929547.
Stebbing, J., Phelan, A., Griffin, I., et al. (2020). COVID-19: Combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases, 20, 400–402. https://doi.org/10.1016/S1473-3099(20)30132-8
Mohanty, S., Harun, A. I., Rashid, M., Mridul, M., et al. (2020). Application of Artificial Intelligence in COVID-19 drug repurposing. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 1027–1031. https://doi.org/10.1016/j.dsx.2020.06.068.
Ke, Y.-Y., Peng, T.-T., Yeh, T.-K., et al. (2020). Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomedical Journal. https://doi.org/10.1016/j.bj.2020.05.001.
Abdelli, I., Hassani, F., Bekkel Brikci, S., Ghalem, S. (2020). In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. Journal of Biomolecular and Structural Dynamics, 1–14. https://doi.org/10.1080/07391102.2020.1763199.
Vincent, M. J., Bergeron, E., Benjannet, S., et al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69
Roshanravan, N., Ghaffari, S., & Hedayati, M. (2020). Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes Metabolic Syndrome, 14, 637–639. https://doi.org/10.1016/j.dsx.2020.05.022
Elfiky, A. A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular and Structural Dynamics, 1–9. https://doi.org/10.1080/07391102.2020.1761882
Beck, B. R., Shin, B., Choi, Y., et al. (2020). Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Computational and Structural Biotechnology Journal, 18, 784–790. https://doi.org/10.1016/j.csbj.2020.03.025
Shah, B., Modi, P., & Sagar, S. R. (2020). In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences, 252, 117652. https://doi.org/10.1016/j.lfs.2020.117652
Kuma, Y., Singh, H., Patel, C. N. (2020). In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infectiona and Public Health. https://doi.org/10.1016/j.jiph.2020.06.016.
Vankadari, N. (2020). Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. International Journal of Antimicrobial Agents, 105998. https://doi.org/10.1016/j.ijantimicag.2020.105998
Yu, R., Chen, L., Lan, R., et al. (2020). Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International Journal of Antimicrobial Agents, 106012. https://doi.org/10.1016/j.ijantimicag.2020.106012.
Sharun, K., Dhama, K., Patel, S. K., et al. (2020). Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of Clinical Microbiology and Antimicrobials, 19, 23. https://doi.org/10.1186/s12941-020-00368-w
Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Development Research. https://doi.org/10.1002/ddr.21656.10.1002/ddr.21656
Gautret, P., Lagier, J.-C., Parola, P., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
Russell, B., Moss, C., Rigg, A., & Van Hemelrijck, M. (2020). COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting? Ecancermedicalscience, 14, 1023. https://doi.org/10.3332/ecancer.2020.1023
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Tripathi, M.K., Sharma, S., Singh, T.P., Ethayathulla, A.S., Kaur, P. (2021). Computational Intelligence in Drug Repurposing for COVID-19. In: Raza, K. (eds) Computational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis. Studies in Computational Intelligence, vol 923. Springer, Singapore. https://doi.org/10.1007/978-981-15-8534-0_14
Download citation
DOI: https://doi.org/10.1007/978-981-15-8534-0_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-8533-3
Online ISBN: 978-981-15-8534-0
eBook Packages: Intelligent Technologies and RoboticsIntelligent Technologies and Robotics (R0)